Multiple sclerosis (MS) is an
|
|
- Annabelle Houston
- 8 years ago
- Views:
Transcription
1 CLINICALLY ISOLATED SYNDROME: EVALUATION, RISK STRATIFICATION, AND TREATMENT DECISIONS * Bruce Cree, MD, PhD, MCR, and Timothy L. Vollmer, MD ABSTRACT Recently a group of community and academic neurologists gathered to discuss current topics of interest in multiple sclerosis (MS). The goal of the meeting was to provide an up-to-date review of the literature and to gather consensus opinions regarding key aspects of each of these topics. This article is the product of one of these sessions that focused on the initial clinical event suggestive of demyelinating disease: the so-called clinically isolated syndrome (CIS). One of the key questions addressed in this monograph is how to stratify risk in the patient with CIS. How useful are brain magnetic resonance imaging (MRI), cerebrospinal fluid analysis, evoked potential tests, and serological assays in determining which patients with CIS will go on to have subsequent attacks and who is at highest risk for neurologic disability? Do recent advances in our understanding of cognitive changes and ultrastructural changes revealed by non-conventional MRI in patients with CIS indicate that more widespread injury to the central nervous system has already occurred at the time of the initial presenting event? Lastly, how useful are disease-modifying *Based on proceedings from a Multisite Think Tank held in September Assistant Professor of Neurology, Multiple Sclerosis Center at UCSF, Department of Neurology, University of California San Francisco, San Francisco, California. Professor of Neurology, Co-Director Rocky Mountain Center for MS Care and Research, Department of Neurology, University of Colorado Health Sciences Center, Aurora, Colorado. Address correspondence to: Bruce Cree, MD, PhD, MCR, Multiple Sclerosis Center at UCSF, 400 Parnassus Avenue, Eighth Floor, San Francisco, CA bruce.cree@ucsf.edu. therapies in preventing further attacks, reducing the accumulation of new lesions apparent on brain MRI, and, most importantly of all, preventing neurologic disability? Does our understanding of MS pathophysiology help support early treatment in MS and CIS? (Adv Stud Med. 2008;8(8): ) Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) and is the most common cause of neurologic disability in young adults. 1 The initial clinical presentation suggestive of relapsing MS is termed the clinically isolated syndrome (CIS). CIS is a neurologic episode caused by inflammation in 1 or more sites within the CNS and lasting at least 24 hours. 2 Diagnosing MS as early as possible is important because the use of disease-modifying therapies (DMTs) early in the course of the disease may significantly slow disease progression. 3-5 DIAGNOSTIC CRITERIA FOR MS Before the use of magnetic resonance imaging (MRI), diagnostic criteria for MS relied exclusively on clinical features. 6 Clinically definite MS was defined by 2 or more relapses, separated by at least 1 month, or a slow, stepwise progressive disease for at least 6 months with documented neurologic signs in more than 1 area of the CNS, thereby defining dissemination of the disease in both space and time. Johns Hopkins Advanced Studies in Medicine 257
2 MRI EVALUATION OF MS Community neurologists recognize the importance of the baseline MRI in CIS. In fact, in an informal survey of community neurologists (N = 43), all agreed that baseline MRIs are necessary during the evaluation of a patient with a CIS. Ninety-eight percent of neurologists suggested that baseline MRI data are very important in counseling patients with CIS about the need to start treatment with DMTs early in the course of disease. Only 2% considered baseline MRIs somewhat important. Also, when it came to counseling patients with CIS on the risk of subsequent attacks, 91% of respondents (N = 44) considered baseline MRI information very important, whereas 9% considered this information somewhat important (Think Tank ARS Data). Indeed, MRI has revolutionized the diagnosis and management of MS. Although characteristic abnormalities are found in 95% of patients with MS, the diagnosis of MS is complicated by the fact that no single clinical feature or diagnostic test is sufficient for the definitive diagnosis of MS and there are several diseases that can mimic MS. 7 Two studies performed early in the history of the clinical use of MRI demonstrated the relationship between CNS lesions on MRI and MS. A study of patients with isolated optic neuritis (ON) revealed a pattern of clinically silent lesions on MRI that were similar in appearance, extent, and location to lesions seen in patients with MS. 8 Another study found that brain stem or spinal cord lesions identified by MRI in patients presenting with their first clinical relapse heralded further attacks consistent with MS. 9 An international panel of MS experts was convened in 2001 to apply an evidence-based approach for developing diagnostic criteria for MS that incorporated findings on brain MRI. 10 To establish a diagnosis of MS, there must be evidence of at least 2 lesions that meet specific diagnostic requirements, disseminated anatomically in space and in time over at least a 30-day period. 10 Certain MRI findings are highly suggestive of MS (Table 1) even before a patient demonstrates dissemination in time The International Panel on the Diagnosis of MS reconvened several years later to update the criteria in order to incorporate new evidence and revise several concepts. They decided that the evidence for dissemination of lesions in time might be more important than that of space. 13 MRI criteria now specified that any new T2 lesion occurring at any point beyond 30 days of the initial clinical event may be used to reach the diagnostic criteria of dissemination in time. The radiographic appearance of an MS spinal cord lesion was specified a lesion must be at least 3 mm in size but less than 2 vertebral segments in length, while occupying only a part of the spinal cord in cross section. Recently, the revised criteria were used to evaluate patients with CIS who were classified as multifocal on the basis of clinical evaluation and MRI. These patients were more likely to fulfill MRI criteria for dissemination in space to reach a diagnosis of clinically definitive MS (CDMS) when compared with patients who had a monofocal CIS presentation. 14 Another study compared the original International Panel Criteria with the modified version and concluded that for patients with CIS, the revised criteria were more accurate (86% vs 73%) and sensitive (77% vs 46%) in predicting the development of CDMS. 15 DIFFERENTIAL DIAGNOSIS The International Panel Criteria emphasize the importance of a differential diagnosis and assert that its use reduces the risk of an incorrect diagnosis because the criteria are based on the specificity of MSlike lesions, which are less likely to occur in conditions that mimic MS. However, several neurologic conditions can mimic the initial clinical presentations of MS, potentially making diagnosis in this setting more challenging (Table 2). The possibility of an alternative diagnosis should be considered when patients are younger than 15 years, or alternatively, older than 60 years. Other fac- Table 1. MRI Criteria for Brain Abnormality A diagnosis of MS is made if 3 of the 4 following criteria are met: 1. One Gd-enhancing lesion or 9 T2-hyperintense lesions if there is no Gd-enhancing lesion 2. At least 1 infratentorial lesion 3. At least 1 juxtacortical lesion 4. At least 3 periventricular lesions Note: One spinal cord lesion may be substituted for 1 brain lesion. Gd = gadolinium; MRI = magnetic resonance imaging; MS = multiple sclerosis. Data from McDonald et al 10 ; Barkhof et al 11 ; and Tintore et al Vol. 8, No. 8 August 2008
3 Table 2. Conditions That May Be Confused with MS Vascular: vasculitis causing multifocal areas of cerebral ischemia or infarction, spinal dural arteriovenous malformations causing progressive paraparesis Infectious: Lyme disease, syphilis and HTLV-1, and Bartonella henselae Tumors: paraneoplastic disorders causing cerebellar ataxia and limbic encephalitis Autoimmune: collagen vascular diseases, such as systemic lupus erythematosus, antiphospholipid antibody syndrome, and Sjögren s syndrome Metabolic: adult-onset leukodystrophies, such as adrenomyeloneuropathy Idiopathic: demyelinating diseases that can be monophasic, including acute disseminated encephalomyelitis, neuromyelitis optica, and acute transverse myelitis Nutritional: vitamin B 12 deficiency Sarcoidosis HTLV-1 = human T-cell lymphotropic virus. tors that point away from a diagnosis of MS are symptoms that locate exclusively to the posterior fossa, craniocervical junction, or spinal cord. Also, although approximately 10% of cases of MS are progressive from onset (primary progressive MS), immediate progression is often a sign that points away from a definitive diagnosis of MS. Furthermore, if patients have not experienced visual, sensory, or bladder symptoms, an alternative diagnosis should be considered. And, finally, atypical or normal laboratory findings, on MRI, cerebrospinal fluid (CSF), and evoked potentials (EPs), may suggest that the patient does not have MS. 7 When attempting to differentiate between possible MS and other neurologic diseases with similar clinical manifestations, clinicians should look for distinguishing clinical, radiologic, prognostic, pathologic, and therapeutic features, in addition to serum biomarkers for other diseases. WHICH PATIENTS WITH CIS ARE AT GREATEST RISK FOR A SECOND ATTACK? The baseline MRI is the most powerful prognostic tool clinically available. In general, at the time of CIS, patients with brain MRI scans revealing either T2 or gadolinium diethylenetriamine-pentaacid (Gd-DTPA)- enhancing lesions are at greater risk for having a second clinical attack diagnostic of MS. 9,11 Patients can be separated into low-, medium-, and high-risk groups for experiencing a second attack depending on the number of brain MRI lesions present at the time of CIS presentation. 16 In contrast, a normal baseline MRI scan is a strong prognostic factor against the development of further attacks, although this is not always the case. 17 Several clinical trials provided a framework for identifying prognosticating factors for the conversion from CIS to CDMS. The treatment trials had similarities and differences; note that the patients were of approximately the same age range and all presented with a CIS (Table 3). 3,4,18 The ONTT (Optic Neuritis Treatment Trial) concluded that the 10-year risk of developing MS after an episode of ON was significantly higher if even a single lesion was seen on MRI. 18 However, increased numbers of MRI lesions were not shown to significantly increase the risk of further attacks. In the ONTT, a lower risk of MS was noted in patients with acute ON associated with male gender, optic disk swelling, no lesions on MRI, as well as features atypical for ON, such as no light perception vision, absence of pain, and ophthalmoscopic findings of severe optic disk edema, retinal exudates, or hemorrhages. These last features likely indicate that the ON in said patients was not a result of MS, but of another ophthalmologic condition. The CHAMPS (Controlled High Risk Subjects Avonex MS Prevention) study group analyzed 190 patients with CIS in the placebo arm with abnormal baseline brain MRIs consistent with demyelination to evaluate the predictive value of existing MS diagnostic criteria. 19 The primary end point was the occurrence of a second clinical attack by 18 months. Two secondary MRI end points were also used: CDMS/MRI 1 (either CDMS or >1 new or enlarging T2 lesion over 18 months) and CDMS/MRI 2 (either CDMS or 1 new or enlarging T2 lesions over 18 months). At 18 months, 27% of all subjects had developed CDMS, and 52% of patients who had 2 or more Gdenhancing lesions at baseline had developed CDMS, compared with only 24% of patients with fewer than 2 Gd-enhancing lesions. The presence of enhancing lesions on the baseline scan was the single best predictor of which patients ended up developing CDMS during the study period. With respect to secondary end points, results were again most pronounced in Johns Hopkins Advanced Studies in Medicine 259
4 patients who had 2 or more Gd-enhancing lesions at baseline. By 18 months, 92% of these patients had reached the CDMS/MRI 1 end point, and 96% had reached the CDMS/MRI 2 end point. Among patients with 4 or more large T2 lesions, 87% developed the CDMS/MRI 1 outcome and 97% developed the CDMS/MRI 2 outcome. Likewise, among patients with 2 or more juxtacortical lesions, 82% reached the CDMS/MRI 1 outcome, and 94% reached the CDMS/MRI 2 outcome. PRESENTATION EFFECTS PROGNOSIS A cohort study of over 2000 patients in France classified patients with MS based on initial symptoms. 20 Isolated ON was the initial presentation in Table 3. Comparison of Patient Cohorts Across 3 Trials on Patients with Early MS/CIS ONTT CHAMPS Study ETOMS Inclusion Criteria Age range, yr Diagnosis Acute unilateral optic neuritis with First isolated, well-defined neurologic event, Clinical syndrome indicating unifocal or visual symptoms of 8 days such as unilateral optic neuritis, incomplete multifocal involvement of the CNS transverse myelitis, or brain stem or with neurologic episode suggesting MS cerebellar syndrome, confirmed by in the previous 3 months examination Imaging Presence of 2 clinically silent lesions of Positive MRI: presence of at least the brain of at least 3-mm diameter on 4 white-matter lesions on T2-weighted MRI (with at least 1 lesion periventricular scan or 3 lesions if at least 1 was or ovoid) infratentorial or enhancing after Gd-DTPA injection Steroids Onset no more than 14 days prior to IV Steroid treatment for moderate steroid therapy started or severe exacerbations EDSS of 3 in 1 functional system or score of 2 in 3 functional systems Exclusion criteria Prior neurologic or visual event lasting Prior immunosuppressive or immuno- >48 hours modulatory treatment, participation in any experimental procedure during the year prior to the study, other serious intercurrent systemic or psychiatric illness, pregnancy, or unwillingness to use reliable methods of contraception during the study Treatment Randomized to receive either: All patients received 1 g of methyl- Randomized to receive either: protocol a) a single course of IV methyl- prednisolone/day IV x 3 days, a) 22 µg IFNβ-1a prednisolone followed by oral followed by 1 mg/kg of prednisone or prednisone by body weight/day orally x 11 days b) placebo or and 4-day period of tapering from injection once weekly for 2 years b) oral prednisone alone 20 mg, 10 mg, 0 mg, and 10 mg. or Then randomized to: c) oral placebo a) 30 µg IFNβ-1a weekly IM injection or b) placebo weekly IM injection CHAMPS = Controlled High Risk Avonex MS Prevention; CIS = clinically isolated syndrome; CNS = central nervous system; EDSS = Expanded Disability Status Scale; ETOMS = Early Treatment of MS Study; Gd-DTPA = gadolinium diethylenetriamine-pentaacid; IFN = interferon; IM = intramuscular; IV = intravenous; MRI = magnetic resonance imaging; MS = multiple sclerosis; ONTT = Optic Neuritis Treatment Trial. Data from Comi et al 3 ; Jacobs et al 4 ; and Beck et al Vol. 8, No. 8 August 2008
5 18% of patients, whereas 9% presented with brain stem dysfunction; 52% presented with isolated corticospinal tract dysfunction, and 21% presented with a combination of symptoms. Disability progression as measured by the Disability Status Scale (DSS) 21 was correlated with the initial presenting symptoms. The DSS score ranges from 0, indicating no neurologic abnormality, to 10, meaning death from MS. Three benchmark scores used were: 4, limited walking but without an aid; 6, walking with a cane; and 7, essentially wheelchair bound. Patients who initially presented with isolated ON had the longest time from onset of symptoms to reach a DSS of 4, at 14.1 years, whereas patients with initial brain stem dysfunction reached the same status at a median of 10.5 years, and those with corticospinal tract dysfunction showed the most rapid deterioration with a DSS of 4 reached at a median 6 years. Another study conducted on patients with CIS (presenting with ON, brain stem/cerebellar syndrome, spinal cord syndrome, hemimotor or hemisensory syndrome, or who were multisymptomatic) assessed the relationship between MRI lesions and transition to CDMS. 22 This study found that 2 or more infratentorial lesions were the best predictors of long-term disability in this cohort. Gd-enhancing and hypointense T1-weighted lesions did not have a prognostic value in these patients. A study from Queens Square in the United Kingdom concluded that patients who presented with CIS, who then subsequently had increased lesion volume on MRI, had corresponding increased degrees of long-term disability from MS. 17 A 14-year controlled, longitudinal study of 57 subjects (28 with CDMS and 29 controls) study found that early, rather than later, focal lesion accumulation predicts development of brain atrophy and correlates with long-term disability. 23 PARACLINICAL MEASURES IN CIS AND MS In addition to MRI data, CSF analysis and EP testing are paraclinical indicators used to confirm the diagnosis of MS. 24 These studies are particularly helpful in clarifying the diagnosis when MRI findings are nonspecific or unusual. 10 In direct contrast to the certainty about the role of MRI data, surveyed neurologists (N = 46) were less certain about whether abnormal EP test results are helpful in predicting a second demyelinating event. Data showed that 43.5% of respondents found abnormal EPs predictive, 20% did not, and 37% said that they were unsure about the predictive potential of abnormal EP results. CSF analysis was favored by the majority of surveyed neurologists (N = 46) when they were asked if they consider the presence of oligoclonal bands in the CNS of patients with ON predictive of MS. Although 15% were unsure about the predictive value of oligoclonal bands in patients with ON, 78% responded that their presence does have predictive value, and only 6.5% suggested that there was absolutely no predictive value (Think Tank ARS Data). Evoked potential testing evaluates the function of afferent or efferent CNS pathways using computer averaging to measure CNS electrical potentials evoked by repetitive stimulation of selected peripheral or optic nerves. Fifty percent to 70% of patients with MS have abnormal results when evaluated. 25 It is important to note, however, that with regards to patients with CIS, one study showed no statistically significant differences on visual EP, brain stem auditory EP, and somatosensory EP testing between patients who did or did not convert to CDMS. 26 Cerebrospinal fluid analysis can enhance the diagnostic process by providing additional insight into the inflammatory and immunologic disturbances that may represent MS. The most common CSF abnormalities found in patients with MS include mononuclear cell leukocytosis and an increased level of intrathecally synthesized immunoglobulin (Ig) G in the form of oligoclonal bands. 7 The utility of checking for CSF abnormalities in helping to establish a clinical diagnosis of MS was supported by a study following 86 patients with ON for a median of nearly 13 years. 27 At onset of ON, CSF pleocytosis and oligoclonal IgG were measured. Abnormal CSF, along with a younger age at onset and early recurrence of ON, correlated with the development of CDMS. Another study found an even stronger correlation between abnormal IgG levels in the CSF relative to abnormal MRI in predicting the conversion of patients from CIS to CDMS. 28 Indeed, intrathecal synthesis of oligoclonal bands correlates closely with MS. Although the intrathecal synthesis of oligoclonal bands was detectable in only 68% of patients with possible onset symptoms of MS, it was detected in 96% of patients with CDMS. 29 The predictive value of abnormal CSF was also observed in an observational cohort that followed patients for up to 30 years after an initial attack Johns Hopkins Advanced Studies in Medicine 261
6 of ON. The risk for a second clinical attack diagnostic of MS increased significantly when oligoclonal IgG bands or a mononuclear pleocytosis were present in the CSF at onset of ON. 30 A new version of CSF analysis intrathecal synthesis of oligoclonal IgG band (OCGB) was shown to have greater sensitivity and specificity compared with older CSF analytical methodologies. The sensitivity for OCGBs in the diagnosis of MS was 96.2% and the specificity was 92.5%. 31 OCGB increases the positive predictive power of MRI. In one study, a group of 52 patients underwent OCGB assessment and was followed for up to 6 years. Ninety-seven percent of OCGB-positive patients with CIS and 15.8% of OCGB-negative patients experienced a second clinical attack. 32 Detection of OCGB in the CSF yielded a sensitivity of 91.4% and specificity of 94.1% for a second clinical attack. Combining OCGB testing and MRI during CIS was very sensitive and moderately specific with regard to predicting a second attack within 6 years. These sensitivity and specificities clearly rival results seen with MRI and prove that CSF studies continue to be an important instrument for diagnosing MS. BIOMARKERS IN CIS The utility of biomarkers for predicting disease progression following CIS is intriguing. One study found that the presence of IgM antibodies directed at myelin basic protein and myelin oligodendroglial protein at the time of CIS were predictive of a second clinical attack diagnostic of MS. 33 Unfortunately, the utility of this technique is uncertain. A subsequent study from a large clinical trial was unable to replicate this observation, 34 whereas a smaller study also found predictive value of these antimyelin autoantibodies. 35 These studies used different techniques and to some extent different patient populations. Thus serologic study of antimyelin antibodies may one day become clinically useful. In the case of neuromyelitis optica (NMO), a CNS demyelinating disease characterized by severe attacks of ON and longitudinally extensive transverse myelitis, a recently developed biomarker can be very useful clinically in distinguishing NMO from typical MS. 36,37 This biomarker is an autoantibody directed against aquaporin 4, 38 a water channel ubiquitously expressed throughout the CNS that regulates flow of water across biologic membranes, such as those found in capillaries and the podocytes of astroglial cells. The presence of this NMO-IgG antibody in patients who suffer from the first attack of longitudinally extensive myelitis is highly predictive of further attacks. 39 IS THERE MORE TO CIS THAN THE ISOLATED LESION? COGNITIVE AND ULTRASTRUCTURAL CHANGES IN CIS AND EARLY MS A group of patients with clinically isolated lesions (ie, a single neurologic deficit) was given a series of neuropsychiatric tests that identified cognitive impairments in the absence of other manifestations of brain pathology, such as physical impairments. The main neurocognitive deficit was that of attention deficit, which was related to the duration of neurologic symptoms and the overall extent of brain pathology as seen on MRI. 40 A more recent study revealed a close relationship between cortical atrophy and cognitive impairment in patients with relapsing-remitting MS. 41 Similar findings were found in a study of patients in the early phase of relapsing-remitting MS, which determined that cognitive impairments noted on neuropsychologic testing were related to loss of brain parenchymal volume more than the extent of brain lesions. 42 This atrophy of brain tissue may be related to early axonal loss, supporting the arguments for early use of DMTs in MS. The limitations of conventional MRI were identified in a study by Filippi et al, which revealed that normalappearing brain tissue (NABT) in fact has changes associated with cognitive deficits in patients with MS. The ultrastructural and functional changes in NABT can be revealed by magnetization transfer histogram analysis. 43 TREATMENT OF CIS AND EARLY MS Axonal transection occurs extensively in actively demyelinating lesions, and therefore irreversible neurologic injury is presumed to begin to occur early in the MS disease process. In an autopsy series of 11 patients with MS, axonal transection was much more abundant in active than in chronic lesions. 44 Some have argued that early intervention with anti-inflammatory MS treatments is justified because axonal transection is irreversible and most abundant in areas of active inflammation. Most treating clinicians agree with this approach. Of surveyed community neurologists (N = 40), 72.5% 262 Vol. 8, No. 8 August 2008
7 cite axonal injury as the cause of disability, compared with 22.5% who feel that demyelination is the pathologic culprit, and 5% who blame oligodendroglial apoptosis (Think Tank ARS Data). It is proposed that by reducing the inflammatory response in the brains of patients with CIS and MS, the long-term consequences of this disease may be prevented. The interferon (IFN) drugs exert an anti-inflammatory effect, which can have a positive impact on patients with MS during the early stages of the disease. Several randomized controlled clinical trials demonstrated improved outcomes for patients with CIS who start therapy with DMTs early in the course of disease. The ETOMS (Early Treatment of MS) study was designed to study the effect of 22 µg subcutaneous IFNβ-1a on the occurrence of relapses in patients who have presented with CIS and are at high risk for second attacks based on the presence of brain MRI lesions. 3 In this 2-year, double-blind, randomized, placebo-controlled trial, 154 of 309 patients were randomized to treatment with once-weekly subcutaneous IFNβ-1a 22 µg. Two hundred and seventy-eight of the patients completed the study. The primary outcome measure was conversion to CDMS, as defined by a second neurologic exacerbation. Brain MRI was performed at 12 and 24 months. The ETOMS study found several benefits of early treatment with IFNβ-1a including: (1) a reduction in conversion to CDMS from CIS; (2) the time to conversion to CDMS by 30% of the cohort was delayed by a factor of more than 2 when compared to the placebo group; (3) a lower annual relapse rate in patients with MS; and (4) fewer new T2-weighted MRI lesions and overall lesion burden on MRI. It should be noted that despite these differences, the vast majority of patients in both groups had evidence of MRI conversion based on the appearance of at least 1 new lesion that was at least 10 mm in diameter or 3 new lesions that were less than 10 mm in diameter, indicating that the underlying pathologic process continued. The CHAMPS study group also validated the benefits of initiating treatment with IFNβ-1a at the time of a first demyelinating event in patients with brain lesions on MRI suspicious for CDMS. 4 In addition to the resultant lower rate in the development of CDMS, patients on IFN had fewer new or enlarging lesions, fewer Gd- DTPA enhancing lesions, and a relative reduction in the volume of brain lesions on MRI compared to the patients in the control group. Over a 3-year period, the rate of development of CDMS from CIS was reduced by 42%. A follow-up study, coined CHAMPIONS (Controlled High Risk Avonex MS Prevention Study in Ongoing Neurologic Surveillance), noted that the development of CDMS continued to remain reduced in patients with CIS 5 years after first event. 45 A statistically significant benefit was seen among patients who started early IFN treatment (within 1 month of the first clinical demyelinating event) compared to those who started treatment at a median of 2.5 years after the first neurologic event. The BENEFIT (Betaferon in Newly Emerging MS for Initial Treatment) trial was designed to study the efficacy, safety, and tolerability of IFNβ-1b (250 µg subcutaneous) administered every other day in highrisk patients who had presented with CIS suggestive of MS and had at least 2 clinically silent T2 lesions. 5 A total of 437 patients between the ages of 18 and 45 were enrolled in this 2-year double-blind, placebocontrolled, randomized, parallel-group trial. In the IFNβ-1b-treated group, the risk for a second clinical attack was reduced by 50% (hazard ratio with 95% confidence interval [CI], 0.5; , P <.0001) and for developing MS based on the International Panel Criteria by 46% (hazard ratio with 95% CI, 0.54; , P <.00001). The probability of reaching MS, according to the International Panel Criteria, was 51% for placebo-treated patients and 28% for IFNβ-1b treated patients. Within 2 years, these probabilities adjusted upward to 85% and 69%, respectively (P <.00001). IFNβ-1b also prevented the development of new inflammatory T2 lesions and decreased the volume of existing hyperintense T2 lesions, suggesting regression of inflammation. Even more importantly, a 40% reduction in disability was demonstrated in those subjects who were treated with IFNβ-1b from disease onset compared to those who either did not receive treatment with IFNβ- 1b or who had a second clinical or radiographic event and received subsequent treatment for conversion to MS. This important observation showed for the first time that early treatment in CIS with IFN was associated with a reduction in neurologic disability and clearly justifies treatment from disease onset. 46 Similar results have recently been reported in a study of treatment with glatiramer acetate (GA) in patients with CIS. In the PRECISE Study, 481 patients with CIS were randomized to treatment with GA or placebo. After 3 years of treatment, the GAtreated patients showed significant decreases in T2, Johns Hopkins Advanced Studies in Medicine 263
8 T1, and Gd-enhancing MRI disease activity when compared to placebo. Also, treatment with GA substantially reduced the risk of conversion to CDMS with an odds ratio of 0.41 (P <.0001). 47 When community neurologists (N = 42) were asked what they thought about treatment with IFNβ after the first demyelinating event, 86% responded that treatment prolongs the time to a second attack, slows progression to confirmed disability, and reduces the burden of disease in T2 MRI. The remaining 14% of respondents felt that it accomplished some, but not all, of these things. Not one respondent suggested that early IFNβ treatment was not helpful in modifying disease progression or manifestation of early disease (Think Tank ARS Data). CONCLUSIONS Available clinical evidence showed that the risk of further attacks in patients with CIS and a positive baseline MRI increases over time to as high as 89%, compared with only an 11% risk in patients with a normal baseline MRI. 17 Many indicators suggest that what happens early in the course of the disease influences outcomes over the long term. Arguments for not initiating early therapy are based on the idea that not all patients progress to CDMS; however, baseline MRI criteria can provide prognostic insight to support treatment decisions. 3 The vast majority of community neurologists believe that baseline MRI data in patients with CIS are critical for counseling patients about short- and longer-term outcomes, as well as the decision to initiate therapy with DMTs (Think Tank ARS Data). This widespread consensus is underscored by strong evidence that shows that treatment with IFNβ or GA reduces the risk of further attacks, lowers MRI disease burden, and slows progression of neurologic disability. REFERENCES 1. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993;20: Clinically Isolated Syndrome (CIS). The National MS Society Web Site. Available at: site/pageserver?pagename=hom_lib_sourcebook_cis. Accessed March 2, Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001;357: Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating even in multiple sclerosis. N Engl J Med. 2000;343: Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67: Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13: Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating disorders. In: Kasper DL, Braunwald E, Hauser SL, et al, eds. Harrison s Principles of Internal Medicine. 16th ed. Vol 2. New York, NY: McGraw Hill Medical Publishing; 2005: Jacobs L, Kinkel PR, Kinkel WR. Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study. Arch Neurol. 1986;43: Miller DH, Ormerod IE, Rudge P, et al. The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. Ann Neurol. 1989;26: McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50: Barkhof F, Filippi M, Miller DH, et al. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120: Tintore M, Rovira A, Martinez M, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol. 2000;21: Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol. 2005;58: Nielsen JM, Moraal B, Polman CH, et al. Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. Mult Scler. 2007;13: Swanton JK, Fernando K, Dalton CM, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatr. 2006;77: Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 2006;67: Brex PA, Ciccarelli O, O Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346: Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121: CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology. 2002;59: Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126: Vol. 8, No. 8 August 2008
9 21. Kurtzke JF. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand. 1970; 46: Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004; 61: Chard DT, Brex PA, Ciccarelli O, et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow-up study. J Neurol Neurosurg Psychiatr. 2003;74: Ghezzi A, Martinell V, Torni V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999;246: Fuhr P, Kappos L. Evoked potentials for evaluation of multiple sclerosis. Clin Neurophysiol. 2001;112: Sastre-Garriga J, Tintore M, Rovira A, et al. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler. 2003;9: Sandberg-Wollheim M, Bynke H, Cronqvist S, et al. A longterm prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. 1990;27: Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol. 1997;41: Sellebjeerg F, Jensen CV, Christansen M. Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis. J Neuroimmunol. 2000;108: Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005;252: Villar LM, Masjuan J, Sadaba MC, et al. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch Neurol. 2005;62: Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, et al. A new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006;66: Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349: Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007;356: Tomassini V, De Giglio L, Reindl M, et al. Anti-myelin antibodies predict the clinical outcome after a first episode of suggestive MS. Mult Scler. 2007;13: Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum antibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364: Wingerchuk D, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66: Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202: Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59: Callanan MM, Logsdail SJ, Ron MA, et al. Cognitive impairment in patients with clinically isolated lesions of the type seen in multiple sclerosis, a psychometric and MRI study. Brain. 1989;112: Morgen K, Sammer G, Courtney SM, et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. NeuroImage. 2006;30: Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatr. 2001;70: Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatr. 2000;68: Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338: Kinkel RP, Kollman C, O Connor P, et al. IM interferon beta- 1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66: Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370: Comi G, Filippi M. Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndromes (CIS). Presented at: Annual Scientific Meeting, American Academy of Neurology; April 12-19, 2008; Chicago, IL. Abstract LBS.003. Johns Hopkins Advanced Studies in Medicine 265
CLINICALLY ISOLATED SYNDROME
CLINICALLY ISOLATED SYNDROME: WHY TO TREAT? * Jacquelyn Bainbridge, PharmD ABSTRACT Clinically isolated syndrome (CIS) is the first symptomatic neurologic episode consistent with multiple sclerosis (MS).
More informationß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
More informationAccuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.
Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.
More informationClinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
More informationMultiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
More informationRational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València
Rational basis for early treatment in MS Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València Bonaventura Casanova Department of Neurology University Hospital La
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationAcute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD
Acute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD Acute demyelinating optic neuritis associated with multiple sclerosis (MS) is
More informationMultiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More informationMRI in Differential Diagnosis
MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards
More information2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
More informationNatural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d
Natural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d Purpose of review To highlight progress in the description of the natural
More informationacquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare
Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated
More informationOHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationOptimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria
Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria AUTHORS Juan Luis Ruiz-Peña, Pablo Duque, and Guillermo Izquierdo Address: Unidad
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationAdvanced Multiple Sclerosis: Progressive MS Epidemiology
Advanced Multiple Sclerosis: Progressive MS Epidemiology CMSC 2007-Washington, DC Mitchell T. Wallin, MD, MPH Associate Director-Clinical Care VA MS Center of Excellence-East East Associate Professor of
More informationClinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationTreatment Optimization in MS: When to Start, When to Shift, when to Stop
Treatment Optimization in MS: When to Start, When to Shift, when to Stop Mark S. Freedman MSc MD FAAN FANA FRCPC Director, Multiple Sclerosis Research Unit University of Ottawa Sr. Scientist, Ottawa Hospital
More informationSTARTING AND SWITCHING MULTIPLE SCLEROSIS THERAPY
STARTING AND SWITCHING MULTIPLE SCLEROSIS THERAPY Steven Galetta, MD University of Pennsylvania Philadelphia, PA LEARNING OBJECTIVES 1. The attendee will be able to describe the features of the radiologically
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationMultiple Sclerosis - Relapsing and Remissioning
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationUsing the MS Clinical Course Descriptions in Clinical Practice
Using the MS Clinical Course Descriptions in Clinical Practice Mark J. Tullman, MD Director of Clinical Research The MS Center for Innovations in Care Missouri Baptist Medical Center Disclosures Consultant/speaking
More informationHow To Use A Drug In Multiple Sclerosis
Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and
More informationThe Many Faces of MS
The Many Faces of MS Patricia A. Modica, OD, FAAO SUNY College of Optometry Kelly Malloy, OD, FAAO Pennsylvania College of Optometry at Salus University Multiple Sclerosis (MS) Most common acquired disease
More informationMultiple Sclerosis. Matt Hulvey BL A - 615
Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationProgress in the field: therapeutic improvements for all patients?
Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationThe Evolution of In Vivo Confocal Microscopy for Quantitative Corneal Imaging W. Matthew Petroll, Ph.D.
Genetics in Eye Disease: From Discovery to Clinical Applications Lucia Sobrin, MD, MPH I. Introduction a. Mendelian Genetic Diseases i. Sequencing b. Complex Polygenic Diseases i. Genome-wide association
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 343 N OVEMBER 16, 2 NUMBER 2 RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS CHRISTIAN CONFAVREUX,
More informationSensitive and reproducible clinical rating
CLINICAL AND MRI MARKERS OF MS DISEASE PROGRESSION * Richard A. Rudick, MD ABSTRACT Sensitive and reproducible measures of multiple sclerosis (MS) severity and progression are important in the treatment
More informationVersion History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b
Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationMULTIPLE SCLEROSIS Update. Disclosures. Multiple Sclerosis. I do not have any disclosures. E. Torage Shivapour, M.D.
MULTIPLE SCLEROSIS Update E. Torage Shivapour, M.D. Clinical Professor Department of Neurology University of Iowa Hospitals & Clinics Disclosures I do not have any disclosures. Multiple Sclerosis Most
More informationConflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
More informationApproved Beta Interferons in Relapsing-Remitting Multiple sclerosis: Is There an Odd One Out?
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Approved Beta Interferons in Relapsing-Remitting Multiple
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationTreatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD
Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More information43. MULTIPLE SCLEROSIS
Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System, as agreed by the Interterritorial Board 43. MULTIPLE
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationHow To Treat Ms With Ifnb-1B
Disease Modifying Therapies in Multiple Sclerosis Report of The Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and The MS Council for Clinical Practice Guidelines
More informationMultiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More information06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
More informationMSTAC Initial Application
MSTAC Initial Application Please send applications to: Facsimile 04 916 7571 Further Contact Details: Address The Co-ordinator MSTAC PHARMAC P O Box 10-254 WELLINGTON Phone 04 460 4990 Email mstaccoordinator@pharmac.govt.nz
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationAUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
More informationHow To Get Ivig To Treat Neuromyelitis Optica
Aetna Customer Resolution Team PO Box 14002 Lexington, KY 40512 RE: Patient Type of service: IVIg Dates of service: To be determined (prior authorization) Dear Sir or Madam: I am writing on behalf of your
More informationNew Horizons in Multiple Sclerosis Management
Disclosures New Horizons in Multiple Sclerosis Management Jody Corey-Bloom, MD, PhD University of California, San Diego Principal Investigator on numerous clinical trials for dementia; support from various
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationAdvances in the Use of MRI in the Management of MS. The Role of MRI in MS Management. Jack H. Simon Portland, Oregon
Advances in the Use of MRI in the Management of MS The Role of MRI in MS Management Jack H. Simon Portland, Oregon Disclosures Dr. Simon has nothing to disclose. This continuing education activity is managed
More informationGrand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com
Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management CME University, FreeCME.com, Powerpak.com Faculty Clyde E. Markowitz, MD Associate Professor of Neurology Director, Multiple
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Association Between Immediate Initiation of Intramuscular Interferon Beta-a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes A -Year Follow-up of the Controlled
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationPROPOSED REVISIONS TO THE CRITERIA. multiple sclerosis (RRMS)] Chapter 6 6 It is recognised that use is in only exceptional circumstances in RRMS.
Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM Condition Name Multiple Sclerosis (MS) Multiple
More informationORIGINAL CONTRIBUTION. Effects of Interferon Beta-1b on Black Holes in Multiple Sclerosis Over a 6-Year Period With Monthly Evaluations
ORIGINAL CONTRIBUTION Effects of Interferon Beta-1b on Black Holes in Multiple Sclerosis Over a 6-Year Period With Monthly Evaluations Francesca Bagnato, MD; Shiva Gupta, BA; Nancy D. Richert, MD, PhD;
More informationOptic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
More informationClinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationMS: The Treatment Paradigm, A Pathway to Success for Improved Patient Outcomes
MS: The Treatment Paradigm, Pathway to Success for Improved Patient Outcomes Jack Burks, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title.
More informationMedication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004
Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationUse of imaging in multiple sclerosis
CHAPTER 3 Use of imaging in multiple sclerosis M. Filippi, 1 M. A. Rocca, 1 D. L. Arnold,2 R. Bakshi,3 F. B ar khof, 4 5 N. De Stefano, F. Fazekas,6 E. Frohman,7 D. H. Mil le r, 8 9 J. S. Wolinsky 1 Institute
More informationMULTIPLE SCLEROSIS 2015. Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine
MULTIPLE SCLEROSIS 2015 Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine Disclosure Research support, Sunovion and Marinus for epilepsy research Goals and Objectives
More informationReversibility of Acute Demyelinating Lesions in relapsingremitting
Reversibility of Acute Demyelinating Lesions in relapsingremitting Multiple Sclerosis Omar A. Khan ( Division of Neuroimmunology, Department of Neurology, Neurology and Research Services. Veterans Affairs
More informationMultiple Sclerosis (Dr. Merchut) 1. Pathophysiology
Multiple Sclerosis (Dr. Merchut) 1. Pathophysiology Multiple sclerosis (MS) is an acquired disorder with immune-mediated destruction of normal central nervous system (CNS) myelin with secondary loss of
More informationDisclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.
Disclosure Statement Multiple Sclerosis: Current Trends in Treatment Member of Speaker s Bureau Biogen Idec Will discuss non FDA approved therapies Christine St Laurent MSN, RN, MSCN 19 th Annual Mud Season
More informationChildhood Multiple Sclerosis and related disorders
Childhood Multiple Sclerosis and related disorders Amna Al-Futaisi, MD, FRCPC Abstract Multiple sclerosis (MS) in children and adolescents is increasingly recognized worldwide. Demyelinating disorders
More informationMultiple sclerosis (MS) is an immune-mediated demyelinating
JAMES R. MILLER, MD ABSTRACT OBJECTIVE: To describe the current understanding of the diagnosis and treatment of multiple sclerosis (MS) and to explore the use of magnetic resonance imaging (MRI) assessment
More informationA Letter From the MS Coalition
0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding
More informationNHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
More informationThe Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
More informationInforming Decisions to Improve the Continuum of Care in Relapsing-Remitting Multiple Sclerosis
Informing Decisions to Improve the Continuum of Care in Relapsing-Remitting Multiple Sclerosis Mirla Avila, MD Texas Tech University Health Sciences Center, Lubbock, Texas Abstract Disease-modifying therapy
More informationNeurosarcoidosis. Jeffrey M. Gelfand, MD
Neurosarcoidosis WASOG Meeting Cleveland October 2012 Patient Education Session Relevant Financial Disclosures: None Jeffrey M. Gelfand, MD Assistant Professor of Clinical Neurology UCSF MS Center, Dept
More informationFeatured Cases: Personalizing DMT Regimens/The Risks Of Medication Non-Adherence
HOME NEWSLETTER ARCHIVE CME INFORMATION PROGRAM DIRECTORS EDIT PROFILE RECOMMEND TO A COLLEAGUE VOLUME 1 ISSUE 2: TRANSCRIPT Featured Cases: Personalizing DMT Regimens/The Risks Of Medication Non-Adherence
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationON NOT Associated with MS
ON NOT Associated with MS Neuromyelitis optica (NMO, Devic s disease) Acute disseminated encephalomyelitis (ADEM) Chronic relapsing inflammatory optic neuropathy (CRION) Post-vaccination-associated optic
More informationDisease Management Consensus Statement
Expert Opinion Paper National Medical Advisory Board Disease Management Consensus Statement Treatment Recommendations for Clinicians This paper is currently undergoing updates from 2008 content. Visit
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationSummary chapter 2 chapter 2
Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological
More informationThe role of MRI in modern management of and treatment decisions in MS
The role of MRI in modern management of and treatment decisions in MS franz.fazekas@medunigraz.at Vienna, September 25, 2013 Department of Neurology, http://neurologie.uniklinikumgraz.at Disclosures 8
More informationOntario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis
May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program
More informationIII./5.3.: Multiple sclerosis. Epidemiology. Etiology. Pathology
III./5.3.: Multiple sclerosis Epidemiology Multiple sclerosis (MS) is the most common neuroimmunological disorder of the central nervous system. This chronic illness begins in early adulthood, mostly at
More informationHow To Know If You Have A Cure For Multiple Sclerosis
DEFINING SUCCESS IN MULTIPLE SCLEROSIS: TREATMENT FAILURES AND NONRESPONDERS * Benjamin Greenberg, MD, MHS, and Elliot M. Frohman, MD, PhD, FAAN ABSTRACT Despite significant therapeutic advances in the
More informationMariusz Stasiołek Neurology Department Polish Mother s Memorial Hospital Research Institute, Lodz
Therapeutic Plasma Exchange in Multiple Sclerosis Relapses Mariusz Stasiołek Neurology Department Polish Mother s Memorial Hospital Research Institute, Lodz MS heterogeneity Multiple Sclerosis differences
More informationWhat is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter
What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted
More informationAbout MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?
An introduction to multiple sclerosis for people who have recently been diagnosed When you have just been diagnosed with multiple sclerosis, you will probably have many questions about the condition and
More information